Although the effects of PTL are mostly associated with its role as an NF-κB inhibitor, some studies have proposed that the overexpression of Shh in breast cancer is due to NF-κB activation (Cui et al., 2010), which apparently cannot explain the phenomenon that PTL promotes Shh expression. Here, NFKB1 is linked to breast carcinoma.